BIO-Europe Spring^® 2012 Press Releases

March 27, 2012BIO-Europe Spring^® 2012 sets new benchmark in attendance and partnering productivityEvent grows more than 20% over previous year
EBD Group, the leading partnering firm for the life science industry, today announced that the sixth annual BIO-Europe Spring^® international partnering conference was attended by 2,157 delegates from 1,304 companies who engaged in 11,172 one-to-one meetings facilitated by partneringONE^®. The event also featured a dynamic program with 135 company presentations, an...more ►

March 22, 2012BIO-Europe Spring^® 2013 to be held in BarcelonaEvent to make Barcelona the hub for biotech dealmaking with more than 2,100 executives from 1,300 companies to engage in productive partnering
EBD Group today announced that the next edition of BIO-Europe Spring^® will be in Barcelona, Spain. Leaders from the global biotechnology industry will gather for the seventh annual BIO-Europe Spring partnering conference on March 11–13, 2013 at the CCIB Convention Centre. The event will attract more than 2,100 executives from 1,300 companies representing over 40 countries wh...more ►

March 21, 2012Novel EUR 150 million collaborative investment announced at BIO-Europe Spring^® 2012 in AmsterdamJohnson & Johnson and GlaxoSmithKline join Index Ventures to form partnership to benefit pre-competitive biotech innovation
Today, the third and final day of BIO-Europe Spring^® 2012, Index Ventures announced the launch of a EUR 150 million life science investment fund with heavy backing from GlaxoSmithKline (GSK) and Johnson & Johnson (J&J). The news was announced at BIO-Europe Spring 2012 in a plenary session entitled "Big pharma and venture capital: Two chefs in the kitchen." BIO-Europe Sprin...more ►

March 5, 2012BIO-Europe Spring^® 2012 program tackles the cutting edge of industry dealmakingKeynote to evoke rich history of the Netherlands and the role of partnering in the Dutch biotech sector
BIO-Europe Spring^® 2012 produced by EBD Group, the leading partnering firm for the life science industry, will be held in Amsterdam March 19–21, 2012 at the Amsterdam RAI Convention Center. This year's exciting event will kick off with opening remarks from Eberhard van der Laan, the Mayor of Amsterdam; David Thomas, Director of Industry Research & Analysis for the Biotec...more ►

February 28, 2012BIO-Europe Spring^® 2012 highlights dynamic deals in Holland's biotech sectorSuccessful partnering is hot topic at Amsterdam conference
BIO-Europe Spring^® 2012 produced by EBD Group, the leading partnering firm for the life science industry, will be held in Amsterdam March 19–21, 2012 at the Amsterdam RAI Convention Center. The event will highlight the biotech and pharmaceutical community in the Netherlands, with a special emphasis on recent Dutch biotech deals and the power alliances that made them happen. ...more ►

February 10, 2012Investment community to come out in full force at BIO-Europe Spring^® 2012Venture capital firms attracted by high level of sophisticated companies involved
Biopharm is gearing up for BIO-Europe Spring^®, EBD Group's springtime life science partnering conference in Amsterdam March 19–21, 2012 at the Amsterdam RAI Convention Center. BIO-Europe Spring attracts some of the best and brightest biotech companies in the sector, and the venture capital community has realized this opportunity by increasing their presence with more represe...more ►

November 21, 2011Global biotechnology industry to gather in Amsterdam for BIO-Europe Spring^® 2012 The global biotechnology industry's top dealmakers and leaders will gather for one of the "must attend" partnering events on the calendar, the sixth annual BIO-Europe Spring^® partnering conference in Amsterdam, March 19–21, 2012 at the Amsterdam RAI Convention Center. This year's edition is enhanced by being held in The Netherlands, a world-class research community ready to...more ►

1 May 2012 Epizyme: Intensive dealmaking in pursuit of personalized therapeutics Little was known about the branch of epigenetics called histone methyltransferases (HMTs) when Epizyme began in late 2007. Yet before the company presented the world's first animal demonstration of efficacy for HMTs in July 2011, it had already attracted USD 54 million in venture investment and USD 45 million in funding from two pharma partners and two foundations. more ►

1 May 2012 Foundation Medicine: Molecular information disrupting the oncology universe The news from Foundation Medicine could not be more encouraging for the company, nor more disruptive for the universe of oncology as we know it today. more ►

20 April 2012 EU medtech management and oversight: New, but complex, proposals A clear, transparent, single mechanism for the oversight and coordination of medtech rules is needed to restore confidence in the European medtech regulatory system which has been badly undermined by recent product safety scandals. more ►

25 March 2012 GSK, J&J back USD 200 million fund for early stage assets The chairmen of Johnson & Johnson Pharmaceuticals and GlaxoSmithKline R&D announced a trailblazing venture fund for fast-tracking early stage assets during the closing plenary session at BIO-Europe Spring^® in Amsterdam. more ►

21 March 2012 Barcelona to welcome BIO-Europe Spring® 2013 The Catalonia biotech sector has developed rapidly in the two years since BIO-Europe Spring^® last visited Barcelona. Major infrastructure has come online, and companies in a start-up phase have now matured in asset development and are ready to partner internationally. more ►